<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Freiburg_CAR skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Freiburg/CAR</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="flex-container1"><DIV class="flex-item2"><DIV class="dropdown"><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Freiburg/Introduction">Overview</A><A href="https://2017.igem.org/Team:Freiburg/Motivation">Motivation</A><A href="https://2017.igem.org/Team:Freiburg/CAR">CAR T Cells</A><A href="https://2017.igem.org/Team:Freiburg/Tumor_microenvironment">Tumor Microenvironment</A><A href="https://2017.igem.org/Team:Freiburg/Design">AND Gate</A><A href="https://2017.igem.org/Team:Freiburg/Outlook">Outlook</A><A href="https://2017.igem.org/Team:Freiburg/Achievements">Achievements</A><A href="https://2017.igem.org/Team:Freiburg/References">References</A></DIV></DIV></DIV><DIV class="flex-item3"><DIV class="dropdown"><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Freiburg/Team">Members</A><A href="https://2017.igem.org/Team:Freiburg/Attributions">Attributions</A><A href="https://2017.igem.org/Team:Freiburg/Sponsors">Partners</A><A href="https://2017.igem.org/Team:Freiburg/Contact">Contact</A></DIV></DIV></DIV><DIV class="flex-item4"><DIV class="dropdown"><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Freiburg/Results">Main Project</A><A href="https://2017.igem.org/Team:Freiburg/Model">Modeling</A><A href="https://2017.igem.org/Team:Freiburg/Applied_Design">Applied Design</A><A href="https://2017.igem.org/Team:Freiburg/Demonstrate">Proof of Concept</A><A href="https://2017.igem.org/Team:Freiburg/Basic_Part">BioBricks Basic Part</A><A href="https://2017.igem.org/Team:Freiburg/Improve">BioBrick Improvement</A><A href="https://2017.igem.org/Team:Freiburg/InterLab">Interlab Study</A></DIV></DIV></DIV><DIV class="flex-item5"><DIV class="dropdown"><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Freiburg/Safety">Safety</A><A href="https://2017.igem.org/Team:Freiburg/Cloning">Cloning</A><A href="https://2017.igem.org/Team:Freiburg/Lab_Knockout"><I>HIF1A</I> Knockdown</A><A href="https://2017.igem.org/Team:Freiburg/Cell_culture">Cell Culture</A><A href="https://2017.igem.org/Team:Freiburg/Notebook">Lab Book</A></DIV></DIV></DIV><DIV class="flex-item6"><DIV class="dropdown"><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Freiburg/HP/Silver">Human Practice</A><A href="https://2017.igem.org/Team:Freiburg/HP/Gold_Integrated">Integrated Human Practice</A><A href="https://2017.igem.org/Team:Freiburg/Collaborations">Collaborations</A></DIV></DIV></DIV></DIV><DIV class="container"><DIV class="row"><DIV class="col-md-12 text-center"><DIV class="flex-container"><H1 align="center">CAR T Cells</H1><DIV class="item"><P>CAR T cells are immune cells that are artificially engineered to express a specific chimeric antigen receptor (CAR), which have demonstrated great potential in fighting cancer.  </P></DIV><DIV class="item"><DIV class="image_box right"><DIV class="figure" style="width:400px;"><DIV class="figureinner"><DIV class="figurecaption"><P style="font-size:14px;"><STRONG>Figure 1: Structure of a Chimeric Antigen Receptor</STRONG>
                           Exemplary is the structure of a chimeric antigen receptor, which is composed of an extracellular recognition domain derived from monoclonal antibodies and an intracellular domain composed of signaling subunits. </P></DIV></DIV></DIV></DIV><P>Chimeric Antigen receptors (CAR) are artificially generated recombinant receptors showing both antigen-binding and T cell activating abilities (Sadelain <I>et al.</I>, 2013). CARs consist of an extracellular recognition domain derived from monoclonal antibodies and an intracellular signaling domain including CD3- and costimulatory domains aiming to trigger endogenous signaling pathways of T cells. The recognition domain of the CAR targets specific molecules expressed on the surface of cancer cells and thereby triggers remarkable responses including activation and killing activity of T cells mediated by the signaling domain (<B>Fig. 1</B>) (Zhang <I>et al.</I>, 2017). As one approach of adoptive cell transfer (ACT), CAR T cell therapy shows reduced toxicity because a patient's own immune cells are collected and modified to treat their cancer.
</P></DIV><DIV class="item"><H2>How does CARTEL<SUP>TM</SUP> Therapy work? </H2><P> T cells are first collected from a patient via apheresis, then cultured and engineered in the laboratory. These engineered T cells are infused into the patient and can express CAR only in the tumor microenvironment and not constitutively as in current CAR therapies (<B>Fig. 2</B>).</P></DIV><DIV class="image_box middle"><DIV class="figure"><DIV class="figureinner"><DIV class="figurecaption"><P><STRONG>Figure 2: Schematic depiction of the CARTEL<SUP>TM</SUP> therapy</STRONG></P></DIV></DIV></DIV></DIV><DIV class="item"><H2>Approved CAR T cell Therapies</H2><P>In the last few years, CAR T cell therapy has achieved much progress. To date, two CAR T cell therapies were approved by FDA. The first one is <A href="https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019" target="_blank">Novartisâ€™ Kymriah</A> for the treatment of young adults with B cell precursor acute lymphoblastic leukemia (ALL) and the second one is <A href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm" target="_blank">Yescarta</A> to treat adults with certain types of large B cell lymphoma.  However, CAR T cell therapy is still facing many challenges (Magee, 2014). So far, most CARs are primarily used against hematopoietic malignancies (including ALL) and not solid cancers. Besides, the potential side effects are still under investigation. We thereby hope to tackle this developing field of synthetic immunotherapy, hoping to make this promising approach safer by controlling the expression of CAR in certain tumor microenvironment, which may allow the development of CARs against <A href="https://2017.igem.org/Team:Freiburg/Outlook">solid tumors</A> .</P></DIV></DIV></DIV></DIV></DIV><DIV class="container"><DIV class="row"><DIV class="col-md-12 text-center"><DIV class="flex-container"><DIV class="col-sm-6"><DIV class="image_box left" style="float:right"><DIV class="figure" style="width:195px"><DIV class="figureinner"><DIV class="figurecaption-car" style="float:right"><P><STRONG>Motivation</STRONG></P></DIV></DIV></DIV></DIV></DIV><DIV class="col-sm-6"><DIV class="image_box right" style="float:left"><DIV class="figure" style="width:200px"><DIV class="figureinner"><DIV class="figurecaption-car" style="float:left"><P><STRONG>Tumor Microenvironment</STRONG></P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>